ALK rearrangement, EGFR mutation, and PDL‐1 testing are all recommended as part of molecular testing for metastatic NSCLC by NCCN in light of the significance of directed treatment for the overall control of lung cancer. This evidence concerns the gene EGFR and lung cancer.